Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. The effect of insulin-like growth factor I (IGF-I) on renal blood flow was measured in the anaesthetized rat using an electromagnetic flow probe. Renal vasodilation induced by IGF-I (50 JLg/kg) was completely inhibited by NG-nitro-l-arginine methyl ester (50 mg/kg) , an inhibitor of nitric oxide biosynthesis, but only partially reduced by indomethacin (10 mg/kg). The involvement of nitric oxide synthesis in the renal actions of IGF-I is proposed.
In the fasted rat, recombinant human insulin-like growth factor I (IGF-I) has been shown to increase both renal plasma flow and the glomerular filtration rate when administered by acute intravenous infusion [1] . A similar increase in both renal plasma flow and glomerular filtration rate from the intravenous administration of recombinant IGF-I has now been reported in two healthy human subjects [2] . The discovery of receptors for IGF-I on the vascular endothelium [3] raises the possibility that the acute renal response to IGF-I could be mediated by endogenous vasodilators synthesized in the endothelium. A role for endothelium-derived relaxing factor (EDRF) in mediating renal vasodilation has recently been identified from experiments in the isolated perfused kidney from the rat [4] . The demonstration of nitric oxide as the chemical entity of EDRF [5] and its synthesis from I-arginine [6] has allowed arginine analogues to be employed as selective inhibitors of nitric oxide biosynthesis [7] . In the present study we have investigated the influence of one such inhibitor NG-nitro-l-arginine methyl ester (I-NAME) on the acute renal vascular response to IGF-I in the anaesthetized rat.
Methods
Male Wi star rats (400 to 450 g), allowed free access to water but not to food in the 12 hour period prior to experiment, were anaesthetized with sodium thiobutabarbitone (In actin) 175 mg/kg i.p. Each rat received a continuous intravenous infusion of sodium chloride 0.45% (100 ILl/min) through a cannula placed in the right jugular vein, while systemic blood pressure was recorded from the left carotid artery. The body temperature of the rat was maintained at 37°C, and renal blood flow recorded as described previously using an electromagnetic flow meter [8] . Briefly, following a retro-peritoneal incision, the left renal artery was cleared and placed in a non-cannulating electromagnetic flow probe (2 mm circumference) attached to a flowmeter (Carolina). When necessary, small arterial branches leaving the right renal artery were tied to ensure a good fit between the renal artery and the probe. Zero flow was established by occlusion of the renal artery distal to the probe.
IGF-I was diluted in isotonic saline to 100 ILg/ml and delivered by short (10 min) continuous i. v. infusion through a syringe pump (Microeject, Carnegie, UK). Neither the additional fluid volume (40 ILl/min) nor the IGF-I drug vehicle had any effect on renal blood flow. L-NAME was dissolved in 0.45% sodium chloride and indomethacin was dissolved in 0.5 M sodium carbonate, and the pH adjusted to pH 8.5. Both I-NAME and indomethacin were each delivered by a lO-minute intravenous infusion, 15 minutes prior to the administration of IGF-1.
All results were expressed as mean ± SEM and compared using the Mann-Whitney test on Microtab software.
Materials were: Recombinant human IGF-I (Kabi-Vitrum, Sweden), I-NAME (Serva, FRG), indomethacin (Sigma Chemical Co., St. Louis, Missouri, USA).
Results
IGF-I (50 ILg/kg) produced a sustained increase in renal blood flow which started to rise at the end of the 10 minute infusion period, reaching its maximum about four to six minutes after the infusion had finished. At this dose the response was sustained and lasted for approximately 30 to 40 minutes. The time course of this response is shown in Figure 1 . At its maximum, IGF-I 50 ILg/kg produced a significant increase in total renal blood flow from 8.5 ± 0.4 to 10.6 ± 0.5 ml/min (P < 0.002, N = 13). This was accompanied by a small but significant fall in systemic blood pressure from 108 ± 5 to 101 ± 6 mm Hg (P < 0.05) and a significant decrease in renal vascular resistance from 13.0 ± 0.6 to 9.7 ± 0.5 mm Hg/ml/min (P < 0.001).
Dose-response experiments to a short intravenous infusion of IGF-I (N = 3) showed a dose-related increase in renal blood flow which could first be detected at a dose of 0.25 ILg/kg.
In a separate series (N = 11), the intravenous administration ofl-NAME 50 mg/kg produced a 51.3 ± 4.2% fall in renal blood flow (P < 0.001, N = 11), the systemic blood pressure increasing from 97 ± 5 to 153 ± 5 mm Hg (P < 0.001; Table 1 ). IGF-I 50 JLg/kg was administered intravenously, 15 minutes after the addition of I-NAME 50 mg/kg. The effect of I-NAME on the renal vasodilation induced by IGF-I is shown in Figure 2 , where the change in renal vascular resistance has been calculated as a percent control of values obtained prior to IGF-I administration. In the presence of I-NAME, IGF-I 50 JLg/kg produced no significant change in renal blood flow (3.3 ± 0.21 to 3.5 ± 0.31 mllmin), systemic blood pressure (153 ± 5.9 to 151 ± 6.1 mm Hg) or renal vascular resistance (48.1 ± 4.6 to 47.2 ± 5.3 mm Hg/mllmin).
In a further series (N = 6), indomethacin (10 mg/kg) had little effect on either basal renal blood flow or systemic blood pressure (Table 1) . The time course of the increase in renal blood flow produced by an intravenous infusion of IGF-I 50 JLg/kg administered 15 minutes after indomethacin 10 mg/kg is 18.0 ± 0.5 16.6 ± 0.5 shown in Figure 1 . IGF-I still produced a significant increase in renal blood flow from 7.4 ± 1 to 8.8 ± 0.2 ml/min (P < 0.05) and
decreased renal vascular resistance from 16.6 ± 0.5 to 13.1 ± 0.5 mm Hg/mllmin (P < 0.05). Although the mean systemic blood pressure was lower at 114 ± 3 mm Hg compared to 127 ± 3 mm Hg, the difference was not significant at the 5% level. However, following indomethacin 10 mg/kg, the maximum increase in renal blood flow produced by IGF-I was significantly lower (30%) than in the control series (P < 0.05).
Discussion
Renal vasodilation induced by IGF-I has previously been demonstrated in the rat fasted for 72 hours to reduce the plasma levels of IGF-I binding protein [1] . The demonstration of increased renal blood flow following the administration of IGF-I to two healthy volunteers [2] indicates that the normal levels of IGF-I binding proteins do not prevent a renal response to exogenous IGF-I from being detected. The results of the present rat experiments support this view since prolonged fasting was not required to demonstrate renal vasodilation in the anaesthetized rat to exogenous IGF-1. A similar total dose of IGF-I, 50 JLg/kg, was employed as in previous rat experiments, but in addition to the increase in renal blood flow a significant fall in systemic blood pressure was observed. This small hypotensive response could be accounted for solely by the change in resistance of the renal vascular bed, indicating that following intravenous administration, IGF-I may exert a selective effect on the kidney. Preliminary dose-response studies showed that renal vasodilation induced by IGF-I could be detected at doses down to 0.25 JLg/kg, representing an addition of approximately 10 ng/ml IGF-I to circulating blood. The electromagnetic flow probe is probably a more sensitive indicator of acute changes in renal blood flow [9] than the method of PAH clearance employed previously [1] .
Following the discovery of I-arginine as the precursor of nitric oxide [6] , I-NAME is one of a number of arginine analogues including monomethylarginine and nitro-arginine now used to inhibit nitric oxide synthesis [7] . Treatment with I-NAME completely inhibited the decrease in renal vascular resistance produced by IGF-I 50 JLg/kg, indicating the involvement of nitric oxide synthesis in this response. Nitric oxide is synthesized in the endothelial lining of blood vessels [5] where the presence of receptors for IGF-I has now been demonstrated [3] . Unlike indomethacin, however, I-NAME had an important effect on basal renal vascular resistance in this preparation, renal blood flow being halved, and renal vascular resistance increasing some 3.5-fold together with a 60 mm Hg increase in blood pressure. An acute increase in blood pressure per se does not prevent the renal vasodilator response to IGF-I, which could still be demonstrated following an increase in blood pressure produced in the rat by an intravenous infusion of noradrenaline (J. Haylor, unpublished observation). Hypertension is a property common to all arginine analogues which are inhibitors of nitric oxide synthesis [7] , indicating an important contribution of nitric oxide to the maintenance of vascular tone. A similar increase in renal vascular resistance to I-NAME has recently been demonstrated in a re-circulating model of the isolated perfused rat kidney [10] .
IGF-I induced renal vasodilation has previously been attributed to an increase in the synthesis of another vasodilator produced by the endothelium, prostacyciin, since the response was reduced by the cycio-oxygenase inhibitor, indomethacin [1]. In the present experiments, however, only 30% of the peak response to IGF-I was abolished by indomethacin 10 mg/kg, a maximal inhibitory dose on the rat kidney [11] . This suggests that following stimulation with IGF-I, there may be a component of the response common to both the nitric oxide and prostacyciin pathways in the kidney. Indomethacin itself had little effect on either renal blood flow or the systemic blood pressure, probablY due to the use retro-peritoneal surgery and the maintenance of an adequate fluid balance.
In addition to increasing renal blood flow, IGF-I can increase the glomerular filtration rate [1,2], and receptors for IGF-I have now been located on the glomerular endothelium [12] . IGF-I may also be involved in compensatory renal growth, since in the rat the renal tissue levels of IGF-I increase following uninephrectomy [13, 14] . The ability of I-NAME to inhibit compensatory growth [15] and of sodium nitroprusside to stimulate mitogenesis [16] have recently been demonstrated. Such observations indicate that a study of the role of nitric oxide in other renal properties of IGF-I warrants further investigation.
